BLISSGVSNSEBliss GVS Pharma Limited· PharmaceuticalsMediumNeutral
Announced Wed, 18 Jun · 18:05 IST

Bliss GVS Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Promoter Below 50pctOwnership Changes View source PDF

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The promoters and promoter group of Bliss GVS Pharma have submitted their yearly declaration under SEBI's takeover regulations for FY ended March 31, 2025. Promoters (Narsimha Shibroor Kamath, Shruti Vishal Rao, Gagan Harsh Sharma, and Dr. Vibha Gagan Sharma) hold 3,71,22,024 shares (35.23% of the company), while smaller promoter group members hold between 0.01% and 0.03%. All promoters declared that they have not created any new encumbrance (pledge, lien, or charge) on their shares during the year, other than what was already disclosed. The number of encumbered (pledged) shares stands at Nil as of March 31, 2025. This is a routine annual compliance filing required from promoters of listed companies.

Likely market impact

Neutral to positive for shareholders — zero pledged shares mean no risk of forced selling by promoters, and the declaration confirms there were no hidden encumbrances created during the year.